Table 3.
Overall Outcomes: BSCVA, Endothelial Cell Density, and Endothelial Cell Loss
| Clinical outcomes | Preoperative (n=600) |
At 3 Months (n=597) |
At 6 Months (n=524) |
At 12 Months (n=374) |
At 24 Months (n=158) |
|---|---|---|---|---|---|
| BSCVA | n (%) | n (%) | n (%) | n (%) | (n; %) |
| ≥20/25 | 0 (0%) | 245 (46.9%) | 243 (48.0%) | 184 (49.2%) | 75 (48.7%) |
| 20/30-20/60 | 39 (6.5%) | 301 (42.7%) | 264 (40.2%) | 153 (40.9%) | 69 (44.9%) |
| <20/60-20/200 | 218 (36.3%) | 49 (8.6%) | 15 (2.9%) | 31 (8.3%) | 8 (5.1%) |
| <20/200 | 343 (57.2%) | 2 (0.3%) | 2 (0.4%) | 6 (1.6%) | 2 (1.3%) |
| ECD (mean±SD); cells/mm2 | 2884±178 | 2223±321 | 2099±354 | 1918±373 | 1772±439 |
| ECL (mean±SD) % | 22.9±11.4% | 27.2±12.4% | 33.5±13.0% | 38.6±14.3% |
BSCVA – best spectacle-corrected visual acuity; ECD – endothelial cell density; ECL – endothelial cell loss